Price$0.23+0.00 (+0.40%)
01:45 PM07:45 PM
News · 26 weeks63+27%
2025-12-142026-06-07
Mix3690d
- Market17(47%)
- SEC Filings9(25%)
- Other8(22%)
- Leadership1(3%)
- M&A1(3%)
Latest news
25 items- PRCosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUNCHICAGO, June 09, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has inaugurated a new, state-of-the-art capsule production line and secured an additional contract manufacturing agreement with Provident Pharmaceuticals ("Provident"), a specialty pharmaceutical company focused on the commercialization and marketing of niche and legacy pharmaceutical products and medical devices in specific therapeutic areas. Under the new five-year agreement, Cana will manufacture 385,000 units of CERTORUN® (sertraline hyd
- PRCosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment InitiativesKEY HIGHLIGHTS Cana Laboratories, Cosmos Health's wholly owned subsidiary, acquires international patent application WO2025108566A1 from Cloudpharm P.C.Patent protection being pursued at national and regional levels across key international marketsTechnology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product developmentExpands nanotechnology investment initiatives, leveraging Cana Laboratories' European GMP-certified manufacturing capabilitiesAligned with the Company's broader strategy of expanding its IP portfolio, strengthening vertical integration, and driving long-term shareholder value CHICAGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Hea
- SECAmendment: SEC Form S-3/A filed by Cosmos Health Inc.S-3/A - Cosmos Health Inc. (0001474167) (Filer)
- SECSEC Form DEFA14A filed by Cosmos Health Inc.DEFA14A - Cosmos Health Inc. (0001474167) (Filer)
- PRCosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform SkroutzCHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand's international reach. A total of 96 Sky Premium Life products are now accessible to consumers across all 27 European Union Member States through Skroutz, with shipments reaching key markets across Western Europe, Northern Europe, and Central and Eastern Europe. The countries covered include Austria, Belgium, Bulgaria, Croatia, Cyprus,
- PRCosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder ValueCompany identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 millionProceeds could fund a meaningful acquisition or eliminate debt entirelyCompany remains fully committed to its core healthcare operations CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is exploring the monetization of non-core assets, having identified approximately $20 million in assets that can be converted to liquidity without impacting the Company's operational capabili
- SECSEC Form DEF 14A filed by Cosmos Health Inc.DEF 14A - Cosmos Health Inc. (0001474167) (Filer)
- PRCosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price DeclineSignificant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while stockholders' equity increased 7.6%Landmark Financing: R&D division in discussions with the European Investment Bank for financing of up to €25 millionCapital Structure Simplification: 4,874,126 Series B Warrants expired unexercised, eliminating ~38% of total warrant overhang with zero shareholder dilutionReal Estate Value: Wholly-owned facilities independently valued at approximately $15 million — exceeding current market capitalization Balance Sheet Transformation: Guidance projects stockholders' equity of $92.3 million by 2029, driven by a growing cash position of $62.9 million fro
- PRCosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash GenerationRevenue increasing 207% at a 32% CAGR: From $65.3 million in 2025 to $200.6 million by 2029, driven by strong growth across all core segmentsGross profit growing 801% to $71.2M: Margins expanding from 12.1% to 35.5% — driven by a structural shift toward high-margin proprietary segmentsNet income improving by $50.1M: Transition to profitability in 2027; net income of $31.0 million by 2029Self-funding growth model: Operating cash flow turning positive in 2027 at $11.9 million, more than doubling to $24.0 million by 2029Balance sheet transformation: Cash up 18-fold to $62.9 million; all convertible notes repaid; cash anticipated to exceed total debt levels by 2027Shareholder value: stockholders
- SECSEC Form PRE 14A filed by Cosmos Health Inc.PRE 14A - Cosmos Health Inc. (0001474167) (Filer)
- SECCosmos Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cosmos Health Inc. (0001474167) (Filer)
- NEWSCosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding WarrantsNo dilution to existing shareholdersReduction in total outstanding warrant overhangSimplifies capital structure CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Series B warrants expired unexercised in accordance with their original terms at 5:00 p.m. New York City time on May 19, 2026.The expired warrants carried an exercise price of $0.95 per share and represented 4,874,126 warrant shares - equal to approximately 38% of the Company's total outstanding warrants.Their expiration eliminates this overhang with no new shares issued and no dilu
- NEWSCosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion UnderwayRecord Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segmentsTotal liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in convertible note and credit facility balancesStockholders' equity increased by $1.4M, or 7.6%, with the liabilities-to-assets ratio improving by 370 basis pointsAdjusted EBITDA near breakeven as increased revenue was offset by strategic investments to support global growthRecord momentum continues into Q2 2026 with U.S. expansion actively underway CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated g
- SECSEC Form 10-Q filed by Cosmos Health Inc.10-Q - Cosmos Health Inc. (0001474167) (Filer)
- SECSEC Form NT 10-Q filed by Cosmos Health Inc.NT 10-Q - Cosmos Health Inc. (0001474167) (Filer)
- NEWSCosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt ProgramAdvisory Agreement Secured: To advance the Company's EIB-backed R&D financing program€25 million potential financing opportunity: Up to 50% of the Company's €50 million planned R&D programInstitutional-grade capital: Potential long-term, attractively structured financing from the EU's premier development bankR&D acceleration: Strengthens and expands the Company's development pipeline across its portfolioValue creation catalyst: Landmark funding opportunity supporting long-term innovation and growth CHICAGO, IL / ACCESS Newswire / May 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced th
- NEWSCosmos Health Announces Withdrawal of Registration Statement on Form S-1CHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a request for withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-283910), originally filed on December 18, 2024 and last amended on June 3, 2025 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.The Registration Statement has not been declared effective and no securities of the Company were sold in connection w
- SECSEC Form RW filed by Cosmos Health Inc.RW - Cosmos Health Inc. (0001474167) (Filer)
- NEWSCosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 MonthsCHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Fort18™ to generate over $3.2 million in incremental annual U.S. revenue within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions. Fort18™ is the latest addition to the Company's "18 Series," a growing portfolio of science-based nutraceutical products. Formulated with a proprietary botanical blend evaluated in published clinical research, Fort18™ enters the U.S. sexual health supplement category targeting men's sexual stamina and endur
- NEWSCosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed2026 revenue forecast raised: Zacks increases 2026 revenue estimate to $103.2 million, up from $98.6 million in its prior January 2026 reportEPS outlook upgraded: Zacks now expects Cosmos Health to cross into positive EPS territory in 2026$4.50 valuation reaffirmed: Updated report maintains valuation target, citing improving fundamentals and operational momentumLong-term growth trajectory maintained: Zacks continues to project revenue of approximately $130.8 million in 2027"Clear inflection point": Zacks highlights Cosmos Health's accelerating operational momentum and strategic evolution into a higher-margin healthcare platform with multiple growth vectors CHICAGO, IL / ACCESS Newswire / May
- NEWSCosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's WellnessScience-based men's wellness: Fort18™ is formulated with a proprietary five-ingredient botanical blend intended to support men's sexual staminaLarge and growing market: The U.S. sexual health supplement market is projected to reach $1.93 billion by 2030Expanding the 18 Series: Fort18™ joins Noor18™, Liv18™, and Cur18™ - advancing the target of 18 science-based products spanning key health categories CHICAGO, IL / ACCESS Newswire / May 6, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the introduction of Fort18™ in the United States - a men's sexual stamina supplement formulated with a p
- NEWSCosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 MonthsCHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18™ to generate over $2.5 million in incremental annual revenue in the United States within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions.Cur18™ is part of the Company's recently introduced "18 Series," a portfolio of science-based nutraceutical products. It is a curcumin-based dietary supplement formulated with a proprietary ingredient that has been evaluated in published pharmacokinetic and clinical studies and is positi
- SECAmendment: SEC Form S-3/A filed by Cosmos Health Inc.S-3/A - Cosmos Health Inc. (0001474167) (Filer)
- NEWSCosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated ProductsScience-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinical trials; a bar the vast majority of the supplement industry cannot meetThree products introduced, $7.8 billion addressable market: Noor18™, Liv18™, and Cur18™ - targeting healthy aging & beauty, liver & metabolic support, and inflammation & mobility across three of the fastest-growing health categories in the U.S.Institutional-grade scientific standard: Patented ingredients, published randomized controlled trials, exact clinical dosing - built to the standard of institutional science, not mark
- NEWSCosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product PortfolioPhase 1 complete: product development, packaging, and initial commercial setup finalized ahead of scheduleProduction commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing - mitigating tariff risk$5M+ projected annual revenue: Liv18™ expected to generate over $5 million annually at approximately 75% gross marginsDirect-to-consumer model: scalable DTC strategy with targeted advertising and disciplined capital allocationEarly U.S. traction confirmed: commercial indicators from existing products shaping revenue expectations and go-to-market strategy CHICAGO, IL / ACCESS Newswire / April 20, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM),
COSM FAQ
5 questionsWhat does Cosmos Health Inc. do?
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and...Where does COSM stock trade?
Cosmos Health Inc. (COSM) is listed on NASDAQ.What sector and industry is COSM in?
Cosmos Health Inc. operates in the Health Care sector, Other Pharmaceuticals industry.What companies are similar to COSM?
Notable peers in the same industry include MCK (McKesson Corporation), COR (Cencora Inc.), CAH (Cardinal Health Inc.), ABC (AmerisourceBergen Corporation), CVET (Covetrus Inc.). Compare COSM side-by-side with any of them on Quantisnow.How can I track COSM on Quantisnow?
Quantisnow aggregates Cosmos Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COSM to receive live email and push alerts on every new disclosure.